NEW YORK, Feb. 4, 2014 (GLOBE NEWSWIRE) -- Context Matters announces that its CEO, Yin Ho, MD, MBA, will participate in a webinar sponsored by Oracle Health Sciences and Pharmaceutical Executive magazine called "Transforming Clinical Development Strategy and Performance with Real-World Data" on February 13, 2014.
Dr. Ho will join a panel with Ken Getz, Senior Research Fellow at the Tufts Center for the Study of Drug Development, and Mukhtar Ahmed, Vice President of Product Strategy at Oracle Health Sciences, moderated by Bill Looney from Pharmaceutical Executive to discuss the topic. The webinar will examine some of the root causes for these issues and present new methods for how trial sponsors can adapt and even prosper in the current environment. Solutions like improving clinical trial design and protocol through "Big Data" and using real-world sources like payers and patient records. The webinar can be registered and accessed through the following link: https://event.on24.com/eventRegistration/EventLobbyServlet?target=registration.jsp&eventid=744865&sessionid=1&key=F929CED41DFAE42EB2CA2F2E5DDE3048&sourcepage=register
Recently, Context Matters published a study in PharmaPhorum, which pointed out that though regulatory approval is still a key step in getting a drug to market, it no longer guarantees market access. The authors discuss how clinical-trial design and the implications on reimbursement can help companies make better use of their resources and expedite the path to a successful drug launch. The paper also indicated that there is also a lack of understanding about the use of trial outcomes and findings outside the realm of Research & Development.
"This is a very important topic in terms of how drug development strategy must change in the age of tightened budgets and increased scrutiny on the part of payors, as well as the increasing attention being paid to 'real-world outcomes,'" said Dr. Ho. "We are very excited to be part of this discussion."
Research from the Tufts Center for the Study of Drug Development indicates that not much has changed in clinical-trial efficiency in the past 50 years. In conjunction, health economics has been having a profound impact on the industry in areas like sponsors' risk, perceived value, and market access strategies.
Context Matters is a leader in the pharmaceutical and biotechnology industry, offering a unique and innovative data-driven software platform that allows customers and users to understand the risk and value of their products by accessing complex data that has never before been quantified or aggregated in a user-friendly, easily navigated manner designed to answer the most pertinent questions facing the pharma/biotech industry today. The RRT has been redefining the way companies approach the drug-development process, by providing a reimbursement perspective to both market access and R&D through an easy-to-use and powerful web-based interface.